BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32059753)

  • 1. miRNA-mRNA Profiling Reveals Prognostic Impact of
    Gadewal N; Kumar R; Aher S; Gardane A; Gaur T; Varma AK; Khattry N; Hasan SK
    Oncol Res; 2020 May; 28(3):321-330. PubMed ID: 32059753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA NEAT1 modulates cell proliferation and apoptosis by regulating miR-23a-3p/SMC1A in acute myeloid leukemia.
    Zhao C; Wang S; Zhao Y; Du F; Wang W; Lv P; Qi L
    J Cell Physiol; 2019 May; 234(5):6161-6172. PubMed ID: 30246348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low SMC1A protein expression predicts poor survival in acute myeloid leukemia.
    Hömme C; Krug U; Tidow N; Schulte B; Kühler G; Serve H; Bürger H; Berdel WE; Dugas M; Heinecke A; Büchner T; Koschmieder S; Müller-Tidow C
    Oncol Rep; 2010 Jul; 24(1):47-56. PubMed ID: 20514443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of NPM1 mutation-modulated microRNA-mRNA regulation in acute myeloid leukemia.
    Chiu YC; Tsai MH; Chou WC; Liu YC; Kuo YY; Hou HA; Lu TP; Lai LC; Chen Y; Tien HF; Chuang EY
    Leukemia; 2016 Feb; 30(2):274-84. PubMed ID: 26376228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
    Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
    Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
    Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
    Haferlach C; Mecucci C; Schnittger S; Kohlmann A; Mancini M; Cuneo A; Testoni N; Rege-Cambrin G; Santucci A; Vignetti M; Fazi P; Martelli MP; Haferlach T; Falini B
    Blood; 2009 Oct; 114(14):3024-32. PubMed ID: 19429869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
    Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
    Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
    Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.
    De Clara E; Gourvest M; Ma H; Vergez F; Tosolini M; Dejean S; Demur C; Delabesse E; Recher C; Touriol C; Martelli MP; Falini B; Brousset P; Bousquet M
    Haematologica; 2017 Oct; 102(10):1718-1726. PubMed ID: 28679652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.
    Seyyedi SS; Soleimani M; Yaghmaie M; Ajami M; Ajami M; Pourbeyranvand S; Alimoghaddam K; Akrami SM
    Tumour Biol; 2016 Apr; 37(4):4841-7. PubMed ID: 26526573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proliferation, migration and apoptosis of acute myeloid leukemia cells regulated by mir-23a-3p targeting SMC1A and the mechanism].
    Zhang YS; Wang MY; Zhang WL; Tang CH
    Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):753-759. PubMed ID: 31648497
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
    Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
    PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.
    Thol F; Bollin R; Gehlhaar M; Walter C; Dugas M; Suchanek KJ; Kirchner A; Huang L; Chaturvedi A; Wichmann M; Wiehlmann L; Shahswar R; Damm F; Göhring G; Schlegelberger B; Schlenk R; Döhner K; Döhner H; Krauter J; Ganser A; Heuser M
    Blood; 2014 Feb; 123(6):914-20. PubMed ID: 24335498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
    Russ AC; Sander S; Lück SC; Lang KM; Bauer M; Rücker FG; Kestler HA; Schlenk RF; Döhner H; Holzmann K; Döhner K; Bullinger L
    Haematologica; 2011 Dec; 96(12):1783-91. PubMed ID: 21880628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts.
    Wang J; Li F; Ma Z; Yu M; Guo Q; Huang J; Yu W; Wang Y; Jin J
    EBioMedicine; 2018 Feb; 28():90-96. PubMed ID: 29402726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
    Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
    Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B.
    Chen Y; Chen S; Lu J; Yuan D; He L; Qin P; Tan H; Xu L
    Medicine (Baltimore); 2021 May; 100(18):e25807. PubMed ID: 33950983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.